Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...